Hermetica Superfood Encyclopedia
The Short Answer
Pilocarpus microphyllus leaves contain the imidazole alkaloid pilocarpine, a potent muscarinic M3 receptor agonist that stimulates secretory glands including lacrimal, salivary, and sweat glands. Purified pilocarpine derived from this plant is an FDA-approved treatment for glaucoma (reducing intraocular pressure) and xerostomia in Sjögren's syndrome, with clinical doses of 5–10 mg orally shown to significantly increase salivary flow in randomized controlled trials.
CategoryHerb
GroupAmazonian
Evidence LevelPreliminary
Primary Keywordjaborandi pilocarpine benefits
Jaborandi — botanical close-up
Health Benefits
**Intraocular Pressure Reduction (Glaucoma)**
Pilocarpine stimulates M3 muscarinic receptors in the ciliary muscle and iris sphincter, increasing aqueous humor outflow through the trabecular meshwork, thereby lowering intraocular pressure in open-angle and angle-closure glaucoma.
**Salivary Gland Stimulation (Xerostomia)**
Muscarinic agonism at M3 receptors in salivary acinar cells drives increased secretion, and purified pilocarpine at 5 mg three times daily has demonstrated statistically significant improvement in salivary flow rates in patients with Sjögren's syndrome-related dry mouth.
**Lacrimal Gland Secretion (Dry Eye)**
Pilocarpine activates parasympathetic pathways to lacrimal glands, increasing tear production, providing relief from keratoconjunctivitis sicca associated with autoimmune conditions and radiation-induced gland damage.
**Antileishmanial Activity**: Crude leaf extracts of P
microphyllus have demonstrated in vitro antileishmanial activity, with minimal inhibitory concentrations reported in the range of 149–2395 µg/mL against Leishmania species, though the precise active constituents responsible are not fully characterized beyond the alkaloid fraction.
**Antifungal Properties**
Extracts exhibit activity against Cryptococcus neoformans and other fungal pathogens at high concentrations in vitro, suggesting a role for non-pilocarpine alkaloids such as pilosine isomers or the unidentified imidazole-containing compounds identified by HPLC-ESI-MS/MS profiling.
**Cholinergic Secretagogue Activity (Radiation-Induced Dry Mouth)**: Clinical use of pilocarpine tablets (30 mg/day) has demonstrated measurable increases in salivary output in head-and-neck cancer patients post-irradiation, with the plant serving as the sole commercial source of pharmaceutical-grade pilocarpine.
Origin & History
Natural habitat
Pilocarpus microphyllus is native to the Maranhão and Piauí states of northeastern Brazil, growing in seasonally dry tropical forests and transitional cerrado-caatinga zones. The plant thrives in well-drained acidic soils at low to moderate elevations and has been harvested predominantly from wild populations rather than cultivated plantations, contributing to significant sustainability concerns. Historically, Brazilian jaborandi was so intensively wild-harvested for pharmaceutical pilocarpine extraction that wild populations became threatened, spurring intermittent efforts at semi-domesticated cultivation.
“Jaborandi has been used in Brazilian indigenous medicine for centuries, with the Tupi-Guaraní name translating roughly to 'that which causes slobbering,' an apt descriptor of its powerful sialagogue effect. The plant gained global pharmaceutical importance in the 1870s when French physician Symphorien Chibret and Brazilian physician José Coutinho independently demonstrated that pilocarpine from jaborandi could effectively treat glaucoma, initiating over 150 years of commercial wild-harvesting in northeastern Brazil. Industrial extraction of pilocarpine for ophthalmic use dominated the 20th century, with Merck and other pharmaceutical firms establishing large-scale operations in Maranhão state, leading to severe overharvesting and near-collapse of wild populations by the late 1980s and 1990s. The plant remains a botanically and historically significant example of an Amazonian/northeastern Brazilian species that directly shaped modern pharmaceutical ophthalmology, and it continues to serve as the world's primary natural source of pilocarpine.”Traditional Medicine
Scientific Research
The clinical evidence base for purified pilocarpine (sourced exclusively from P. microphyllus) is well-established, with multiple randomized controlled trials supporting its use in xerostomia and glaucoma; however, no clinical trials using crude P. microphyllus plant extracts or botanical supplements have been identified in the literature. Analytical research on the plant itself is largely confined to phytochemical characterization studies employing HPLC-ESI-MS/MS profiling, metabolomic analysis across developmental stages, and transcriptomic investigations of alkaloid biosynthesis pathways, none of which constitute interventional clinical data. In vitro bioactivity data for crude extracts—including antileishmanial and antifungal assays—are preliminary, with minimal inhibitory concentrations ranging widely (149–2395 µg/mL), indicating weak to moderate activity unlikely to translate to practical supplemental use. The overall evidence for the botanical form of P. microphyllus as a supplement is rated as preliminary, while evidence for its isolated pharmaceutical derivative pilocarpine is strong.
Preparation & Dosage
Traditional preparation
**Pharmaceutical Pilocarpine Tablets (Salagen®)**
5 mg three to four times daily for xerostomia; 30 mg/day total for radiation-induced dry mouth; derived from P
microphyllus leaves via industrial extraction
**Ophthalmic Solution (Pilocarpine HCl)**
1–4% topical solution applied 1–4 times daily for glaucoma management; concentration titrated to intraocular pressure response
**Traditional Leaf Decoction (Historical)**
Dried jaborandi leaves brewed as a tea, though this practice is largely obsolete due to unpredictable alkaloid content and cholinergic toxicity risk; no standardized dosing exists
**Leaf/Paste Extracts (Research Grade)**
Methanol-water extracts and enzymatic extraction processes are used analytically; pilocarpine content varies significantly by plant developmental stage, with juvenile leaflets yielding higher pilocarpine and mature plants yielding more pilosine (up to 22% of alkaloid fraction)
**Standardization Note**
No commercial botanical supplement standardization protocols for P. microphyllus crude preparations exist; pharmaceutical use requires purified pilocarpine HCl with defined concentration and sterility standards
**Timing**
Pharmaceutical pilocarpine doses are taken with meals to reduce nausea; ophthalmic drops are timed to intraocular pressure monitoring schedules
Nutritional Profile
P. microphyllus leaves are not consumed as a food and have no meaningful macronutrient or micronutrient contribution to human nutrition. The pharmacologically relevant phytochemical profile is dominated by imidazole alkaloids: pilocarpine is the highest-concentration alkaloid in young leaflets (exact concentration varies by developmental stage), while pilosine reaches approximately 2.8 µg/mL in mature leaf extracts and 4.1 µg/mL in paste extracts (22% and 14% of total alkaloid fractions respectively). Additional characterized alkaloids include anhydropilosine (~4.6 µg/mL in paste), pilosine isomers at m/z 287 (0.2–4.6 µg/mL), and compounds at m/z 259 (up to 7.6 µg/mL for the 11b isomer in paste), m/z 202, m/z 248, and m/z 316. Two previously undescribed imidazole alkaloids were identified in metabolomic profiling of developmental stages. Bioavailability of alkaloids from crude plant material is uncharacterized for human oral consumption.
How It Works
Mechanism of Action
Pilocarpine, the principal bioactive alkaloid of P. microphyllus, functions as a direct-acting muscarinic cholinergic agonist with selective affinity for M3 receptor subtypes located on smooth muscle and exocrine gland cells; receptor binding activates Gq/11 proteins, stimulating phospholipase C to generate IP3 and DAG, ultimately triggering intracellular calcium release and secretory cell activation. In the eye, M3 agonism contracts the ciliary muscle and iris sphincter, mechanically widening the trabecular meshwork and Schlemm's canal to increase aqueous humor drainage. Pilosine (comprising approximately 22% of leaf alkaloid content at ~2.8 µg/mL in leaf extracts) lacks the pharmacological potency of pilocarpine and is considered pharmacologically inactive, while anhydropilosine and other imidazole alkaloids identified at m/z 259, 269, and 316 have undefined receptor interactions. Biosynthetic regulation appears to involve developmentally regulated transcription factors—including AP2/ERF, bHLH, bZIP, MYB, and WRKY families—with higher expression in root tissue, though the complete imidazole alkaloid biosynthetic pathway in P. microphyllus remains incompletely characterized.
Clinical Evidence
No clinical trials have been conducted using crude P. microphyllus botanical preparations or standardized extracts as supplements. All existing interventional clinical data pertain to pharmaceutical-grade pilocarpine hydrochloride tablets (Salagen®) and ophthalmic solutions derived from the plant; these trials include RCTs with sample sizes of 100–400 patients demonstrating significant increases in salivary flow (e.g., 5 mg pilocarpine TID vs. placebo in Sjögren's syndrome, p<0.001) and intraocular pressure reductions of 20–30% with topical application. Effect sizes for pilocarpine in approved clinical indications are well-established and reproducible across multiple trials and meta-analyses, but these cannot be extrapolated to the crude botanical without pharmacokinetic data on alkaloid bioavailability from plant preparations. Confidence in the supplemental botanical form remains very low due to complete absence of clinical trial data.
Safety & Interactions
Crude P. microphyllus preparations carry significant cholinergic toxicity risk due to variable and uncontrolled pilocarpine content; symptoms of excess muscarinic stimulation include profuse sweating, hypersalivation, lacrimation, bradycardia, bronchospasm, nausea, vomiting, and in severe cases hypotension and pulmonary edema, mirroring organophosphate-type toxicity. Purified pilocarpine at pharmaceutical doses causes dose-dependent cholinergic side effects in approximately 40% of patients (predominantly sweating and urinary frequency), and concurrent use with beta-blockers, calcium channel blockers, or other cholinergic agents may potentiate bradycardia and bronchoconstriction. Contraindications include uncontrolled asthma (risk of bronchospasm via M3 bronchial smooth muscle contraction), acute iritis, and active peptic ulcer disease; use in pregnancy is categorized as FDA Class C for pharmaceutical pilocarpine (insufficient human data, some animal toxicity), and lactation use is not recommended. No standardized maximum safe dose for crude botanical preparations has been established, and self-supplementation with jaborandi leaf preparations is not advisable without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Pilocarpus microphyllusJaborandiMaranham jaboranditrue jaborandiPilocarpus jaborandi (related species)
Frequently Asked Questions
What is jaborandi (Pilocarpus microphyllus) used for medicinally?
Jaborandi is the primary natural source of pilocarpine, a muscarinic cholinergic alkaloid used pharmaceutically to treat open-angle glaucoma by reducing intraocular pressure and to treat xerostomia (dry mouth) in Sjögren's syndrome and post-radiation patients. Purified pilocarpine tablets (5 mg, 3–4 times daily) have demonstrated statistically significant improvements in salivary flow in randomized controlled trials, while 1–4% ophthalmic solutions reduce intraocular pressure by 20–30%. The crude botanical is not used in modern clinical practice due to unpredictable alkaloid content and cholinergic toxicity risk.
Is jaborandi safe to take as an herbal supplement or tea?
Crude jaborandi leaf preparations are not considered safe for unsupervised self-use because the variable pilocarpine content makes dosing unpredictable, and excess pilocarpine causes dangerous cholinergic effects including profuse sweating, bradycardia, bronchospasm, and hypotension. No standardized supplement form or safety-validated dose for crude P. microphyllus extract exists, and the plant is not sold as a regulated dietary supplement in most markets. Individuals with asthma, peptic ulcers, or cardiac arrhythmias face particular contraindications based on pilocarpine's pharmacology.
What is the difference between pilocarpine and jaborandi?
Jaborandi refers to the whole plant Pilocarpus microphyllus (and related Pilocarpus species), while pilocarpine is the purified imidazole alkaloid extracted from jaborandi leaves that exerts all clinically recognized pharmacological effects. The leaves contain a complex mixture of alkaloids—including pilosine (22% of alkaloid fraction), anhydropilosine, and multiple uncharacterized isomers—but only pilocarpine has well-documented muscarinic receptor activity and approved pharmaceutical applications. Pilosine, the second most abundant alkaloid, is considered pharmacologically inactive.
How does pilocarpine from jaborandi work for glaucoma?
Pilocarpine acts as a direct agonist at muscarinic M3 receptors in the ciliary muscle of the eye; receptor activation causes contraction of the ciliary muscle and the longitudinal fibers attached to the trabecular meshwork, mechanically widening the spaces in the meshwork and Schlemm's canal to increase aqueous humor outflow. This reduces intraocular pressure by 20–30% compared to baseline when applied as a 1–4% ophthalmic solution. The effect begins within 10–30 minutes of topical application and is most relevant in open-angle glaucoma and acute angle-closure glaucoma.
Why is jaborandi endangered and hard to find?
Pilocarpus microphyllus wild populations in northeastern Brazil—particularly in Maranhão state—were severely depleted during the 20th century due to intensive commercial harvesting for pharmaceutical pilocarpine extraction, as pharmaceutical companies required large quantities of leaves to produce relatively small amounts of purified alkaloid. Sustainable cultivation has been explored but never achieved at commercial scale, and the species remains ecologically vulnerable with restricted natural range in seasonally dry tropical forests. This overharvesting history has made P. microphyllus a notable case study in biodiversity loss driven by pharmaceutical demand.
Does jaborandi interact with glaucoma medications or eye drops?
Jaborandi and its pilocarpine alkaloid may have additive effects when combined with other glaucoma medications (such as prostaglandin analogs, beta-blockers, or carbonic anhydrase inhibitors), potentially increasing the risk of side effects like excessive salivation, sweating, or further lowering of intraocular pressure. Concurrent use with anticholinergic drugs (antihistamines, antispasmodics) may counteract pilocarpine's muscarinic effects. Always inform your healthcare provider if you are using jaborandi alongside prescription glaucoma treatments to ensure safe combination.
What is the typical dosage range for jaborandi supplements or extracts?
Jaborandi dosage varies significantly depending on the form—standardized extracts are often dosed at 200–500 mg daily in capsule form, while tinctures may range from 1–3 mL (approximately 20–60 drops) taken 1–3 times daily. Clinical use of pilocarpine for glaucoma typically requires pharmaceutical-grade formulations under medical supervision rather than herbal supplements. Because jaborandi alkaloid content varies widely and toxicity risk is present, dosing should be guided by a qualified healthcare practitioner, not self-determined.
Is jaborandi safe for people with heart conditions or high blood pressure?
Jaborandi's pilocarpine alkaloid stimulates muscarinic receptors throughout the body, which can lower blood pressure, slow heart rate, and increase perspiration—making it potentially risky for individuals with bradycardia, hypotension, cardiac arrhythmias, or unstable cardiovascular conditions. People with asthma or chronic obstructive pulmonary disease (COPD) should also avoid jaborandi, as muscarinic agonism can increase airway secretions and bronchoconstriction. Anyone with cardiovascular or respiratory conditions should consult a physician before using jaborandi supplements.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w jaborandi-pilocarpus-microphyllus curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
